Related Experiment Video
Updated: Jul 13, 2025
06:09
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
8.8K
PAK1 and Therapy Resistance in Melanoma
Julia V Kichina1, Alexei Maslov2, Eugene S Kandel2
1Department of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton St., Buffalo, NY 14263, USA.
Cells
|October 13, 2023
Summary
Targeting p21-regulated kinase 1 (PAK1) may improve melanoma treatment. Inhibiting PAK1 enhances sensitivity to cell death and reduces tumor growth, potentially improving current therapies for metastatic melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Metastatic melanoma has a poor prognosis despite available therapies.
- Current treatments for metastatic melanoma lack curative efficacy for most patients.
- p21-regulated kinase 1 (PAK1) pathways are implicated in melanoma progression and treatment response.
Purpose of the Study:
- To review the role of PAK1 in melanoma response to therapy.
- To explore how PAK1 inhibition can enhance anti-melanoma treatment efficacy.
- To identify challenges in implementing PAK1-targeted strategies.
Main Methods:
- Literature review of studies investigating PAK1 in melanoma.
- Analysis of data on PAK1's influence on cell death, growth pathways, and the tumor microenvironment.
- Evaluation of evidence for combined PAK1 inhibition with existing therapies.
Main Results:
- PAK1 may reduce sensitivity to programmed cell death in melanoma cells.
- PAK1 can stimulate growth-promoting pathways and create an immunosuppressive tumor microenvironment.
- Concomitant inhibition of PAK1 shows potential to enhance various anti-melanoma treatments.
Conclusions:
- PAK1 plays a significant role in melanoma's resistance to therapy.
- Inhibiting PAK1 could improve the effectiveness of current melanoma treatments.
- Developing safe and effective PAK1 inhibition strategies is crucial but challenging.
Related Concept Videos
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K